gastroesophageal cancer
AstraZeneca, Daiichi Sankyo Begin First-Line Trial of Enhertu, Keytruda Combo in Gastric Cancer
The trial will include patients with locally advanced or metastatic HER2-positive, PD-L1-positive gastric or gastroesophageal junction cancer.
I-Mab Advances Phase Ib Trial of Givastomig in CLDN18.2-Expressing Gastric Cancers
The firm completed enrollment of the first dose expansion cohort evaluating givastomig with immunotherapy and chemotherapy.
BeiGene Nabs FDA Approval for Tevimbra With Chemo in First-Line PD-L1-Positive Gastric Cancer
Patients on the Tevimbra combo had a 20 percent reduction in risk of death compared to those on chemotherapy alone.
Carsgen to Seek Approval in China for Satri-Cel in Claudin18.2-Expressing Gastric Cancer
The firm said the Phase III trial met its primary endpoint of improvement in progression-free survival.
European Commission Approves BeiGene's Tevimbra, Chemo in First-Line Gastric, Esophageal Cancers
The EC considered the treatment's activity in patients with advanced, PD-L1-positive esophageal and gastric cancers in the RATIONALE-305 and -306 trials.
Aug 27, 2024